Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02085473 · ClinicalTrials.gov registry record · Phase 1
A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02085473 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 60 participants.
The verdict
NCT02085473, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) and tolerability of tralokinumab when delivered subcutaneously at different flow rates to healthy volunteers.
Interventions
- BIOLOGICAL Tralokinumab 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-03-19 |
| Est. Completion | 2014-07-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02085473
The ClinicalTrials.gov registry entry for NCT02085473 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tralokinumab 300 mg is the first listed.
NCT02085473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02085473 about?
NCT02085473 is a clinical study titled "A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers". The primary objective of this study is to evaluate the pharmacokinetics (PK) and tolerability of tralokinumab when delivered subcutaneously at different flow rates to healthy volunteers.
What is the current status of trial NCT02085473?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2014-03-19. Estimated completion is 2014-07-10.
What interventions are being tested in trial NCT02085473?
The interventions under investigation include: Tralokinumab 300 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT02085473?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.